Enlivex Therapeutics Ltd (ENLV) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $1.15
• Market Cap: $261.12M
• EPS: $-0.54
• 52-Week High: $2.10
• 52-Week Low: $0.66

Market Sentiment

Enlivex Therapeutics Ltd currently has a Bullish sentiment score of 0.27.

About Enlivex Therapeutics Ltd

Enlivex Therapeutics Ltd. is a clinical-stage biopharmaceutical company headquartered in Nes Ziona, Israel, specializing in the development of innovative immunotherapeutic solutions through its proprietary Alum-based platform designed to modulate the immune system. The company focuses on addressing critical conditions, including cancer and autoimmune disorders, by harnessing its unique technologies to improve therapeutic outcomes. With a promising pipeline and a dedication to advancing immune...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Enlivex Therapeutics Ltd and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does ENLV pay dividends?

Enlivex Therapeutics Ltd (ENLV) does not currently pay a regular dividend.

What is ENLV's market cap?

Enlivex Therapeutics Ltd (ENLV) has a market capitalization of $261.12M with a current stock price of $1.15.